Healthcare Services

Visceral Leishmaniasis Market Future Trends and Growth Forecast

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Visceral Leishmaniasis Market Between 2026 And 2030?

The visceral leishmaniasis market has demonstrated significant expansion in recent years. It is anticipated to increase from $1.06 billion in 2025 to $1.12 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.9%. This historical growth can be attributed to several factors, including the increasing prevalence of the endemic disease, a rise in public health awareness initiatives, the presence of established antiparasitic treatments, the development of hospital-based treatment programs, and support from international health organizations.

The visceral leishmaniasis market is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.39 billion, achieving this with a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period stems from several factors, including heightened investments in new therapeutic approaches, a greater emphasis on developing vaccines and immunotherapies, broader adoption of molecular diagnostics, increased governmental financial support for eliminating the disease, and improved access to treatment within affected regions. Key trends during this period are expected to encompass a wider uptake of sophisticated diagnostic methods, an increased application of combination drug treatments, a sharpened focus on detecting the disease earlier, an expansion of public health screening initiatives, and a boosted commitment to making treatments more accessible.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

Which Drivers Are Supporting The Visceral Leishmaniasis Market Growth?

The anticipated expansion of the visceral leishmaniasis market is linked to an increase in malnutrition. Malnutrition, characterized as a health issue stemming from insufficient or unbalanced nutrient consumption vital for proper bodily function, is on the rise. This surge in malnutrition is largely attributed to food insecurity, which restricts access to nutritious food, leading to conditions like undernourishment and micronutrient deficiencies that compromise the immune system. Such nutritional deficiencies hinder immune function, leaving individuals more susceptible to various infections, including visceral leishmaniasis. A weakened defense due to lack of nutrients elevates the chances of developing severe illness and complications. For example, in July 2024, the United Nations Children’s Fund (UNICEF), a U.S.-based specialized agency, reported that approximately 733 million people worldwide were undernourished in 2023. Consequently, the growing prevalence of malnutrition is a key factor fueling the growth of the visceral leishmaniasis market.

How Is The Visceral Leishmaniasis Market Categorized Across Its Segment Groups?

The visceral leishmaniasis market covered in this report is segmented –

1) By Treatment: Antiparasitic, Antifungal, Other Treatments

2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods

3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy

2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes

3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy

Which Trends Are Expected To Impact The Visceral Leishmaniasis Market?

Major companies within the visceral leishmaniasis market are prioritizing the advancement of treatment solutions, including antiparasitic drugs, to enhance their effectiveness and improve patient access, particularly in areas where the disease is prevalent. Antiparasitic drugs are medicines employed to combat infections caused by parasites by specifically targeting the parasite’s biological functions, thereby interrupting its growth, multiplication, or continued existence within the host. For instance, in February 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, obtained World Health Organization (WHO) prequalification approval for the active pharmaceutical ingredient (API) and formulation of miltefosine for addressing leishmaniasis or kala-azar. Miltefosine operates as an oral antiparasitic drug by disrupting the parasite’s cell membrane and interfering with its metabolic processes, which leads to cell death. It also hinders parasite proliferation and survival, making it an effective oral therapeutic option for visceral leishmaniasis or kala azar.

Which Firms Are Influencing Competition In The Visceral Leishmaniasis Market?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., GSK plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd., Xellia Pharmaceuticals, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, Sanofi SA, Bharat Serums and Vaccines Limited, Emcure Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Ipca Laboratories Limited, Intas Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, Mankind Pharma Limited, Alembic Pharmaceuticals Limited

Get The Full Visceral Leishmaniasis Market Report:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

Which Region Is The Leading Market For The Visceral Leishmaniasis Market?

North America was the largest region in the visceral leishmaniasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Visceral Leishmaniasis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

Browse Through More Reports Similar to the Global Visceral Leishmaniasis Market 2026, By The Business Research Company

Anticoagulant Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Psoriasis Drugs Market Report

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Veterinary Parasiticides Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-parasiticides-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795